Hydal (Hydromorphone Hydrochloride)

Hydal is indicated for several types of pain that require strong opioid therapy. It is typically prescribed when other analgesics are inadequate.

• Management of moderate to severe acute pain, such as postoperative pain.
• Treatment of chronic cancer‑related pain.
• Relief of severe breakthrough pain in patients already on opioid therapy.
• Use in palliative care settings for symptom control.
• Short‑term control of severe musculoskeletal pain when non‑opioid options are ineffective.

• Hydal’s active ingredient, hydromorphone hydrochloride, binds selectively to the µ‑opioid receptors in the central nervous system. Activation of these G‑protein‑coupled receptors inhibits the release of neurotransmitters involved in pain transmission, leading to reduced perception of pain. The drug also modulates neuronal excitability and decreases the ascending pain pathways, producing analgesia while also affecting reward and respiratory centers.

Hydal may cause a range of adverse reactions, some of which are more frequently observed than others.

Common

• Constipation
• Nausea and vomiting
• Drowsiness or sedation
• Dizziness
• Dry mouth
• Sweating

Serious

• Respiratory depression
• Severe hypotension
• Allergic reactions (rash, itching, swelling)
• Dependence or withdrawal syndrome
• Severe confusion or delirium

Before starting Hydal, patients should be evaluated for factors that may increase risk of adverse outcomes.

• Assess for a history of respiratory disorders, such as sleep apnea or chronic obstructive pulmonary disease.
• Use caution in patients with severe hepatic or renal impairment.
• Avoid use during pregnancy or breastfeeding unless clearly indicated.
• Monitor for signs of opioid dependence, tolerance, or misuse.
• Adjust dose in elderly patients due to increased sensitivity.
• Counsel patients about the risk of constipation and provide preventive measures.

Hydal can interact with several other medications, affecting its safety and efficacy.

Avoid

• Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates, alcohol).
• Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, which may increase hydromorphone levels.
• MAO inhibitors, due to risk of severe serotonin syndrome.

Use with caution

• Mixed agonist‑antagonist opioids (e.g., buprenorphine) which may precipitate withdrawal.
• CNS stimulants that may mask sedation.
• Medications that prolong QT interval, requiring cardiac monitoring.
• Drugs that affect renal or hepatic function, potentially altering drug clearance.